19th Jul 2007 07:00
Futura Medical PLC19 July 2007 For immediate release 19 July 2007 Futura Medical Plc ("Futura" or "the Company") Result of AGM Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovativeproducts for consumer healthcare, held its Annual General Meeting yesterdayafternoon at which all resolutions were duly passed. At the AGM, the Company's Chairman, Dr William Potter, made the followingcomments: "As we reported at the time of our preliminary results, we are movingcloser to EU regulatory approval of CSD500, which will be launched under theDurex(R) brand by our partner SSL International plc. Regulatory approvalremains on track for Q4 of this year and we look forward to making thetransition to a revenue generating business with a recurring royalty stream. "Also, as mentioned at the time of our preliminary results, we have beenencouraged by the level of interest from potential licensing partners inMED2002, our OTC treatment for erectile dysfunction. Out-licensing negotiationsare continuing and we remain confident that a licensing partner will be securedon attractive commercial terms in due course. "We continue to make progress on our earlier-stage portfolio and in seeking newapplications for our novel drug delivery technology, DermaSys(R)?." In accordance with AIM Rule 17, Futura Medical notes the transfer of ordinaryshares in the Company by the following Directors, though there has been nomaterial change to the total shareholdings of any of the Directors: James H Barder, Chief Executive 1 Feb 05: Transfer of 236,997 Futura shares from paper certificate (in the nameof James Barder) into Carr Sheppards nominee account (Ferlim Nominees) for theaccount of James Barder 4 Feb 05: Transfer of 250,000 Futura shares from paper certificate (in the nameof Charlotte Barder) into Carr Sheppards nominee account (Ferlim Nominees) forthe account of Charlotte Barder 23 Feb 05: Sale of 11,000 Futura shares from James Barder and purchase of 11,000Futura shares into Sippdeal Trustees Ltd for the account of James Barder 26 Feb 07: Sale of 74,500 Futura shares from James Barder and purchase of 74,500Futura shares into Sippdeal Trustees Ltd for the account of James Barder David B Davies, Product Development Director 13 July 2005: Sale of 15,152 Futura shares from David Davies and purchase of15,152 Futura shares into Hargreaves Lansdown Vantage SIPP for the account ofDavid Davies 26 Mar 07: Sale of 61,084 Futura shares from David Davies and purchase of 60,381Futura shares into Hargreaves Lansdown Vantage SIPP for the account of DavidDavies. The balance of 703 Futura shares not purchased in to the HargreavesLansdown Vantage SIPP covered dealing costs associated with the transaction. For further information: Futura Medical plcJames Barder, Chief Executive Tel: +44 (0) 1483 685 670mail to: [email protected] www.futuramedical.co.uk Buchanan CommunicationsMark Court / Rebecca Skye Dietrich Tel: +44 (0) 020 7466 5000 Canaccord AdamsMark Ashurst / Tyler Broda Tel: + 44 (0) 20 7050 6500 Notes to Editors Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products forconsumer healthcare. The Company is developing a portfolio of products and itsstrategy is to license their manufacture and distribution to majorpharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market ofthe London Stock Exchange. www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Futura Medical